- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07570251
Evaluation of Cognitive Education Activities in Breast Cancer Patients Receiving Chemotherapy
Evaluation of Cognitive Education Activities Provided to Breast Cancer Patients Receiving Chemotherapy
Breast cancer is one of the most common cancer types worldwide and accounts for approximately 31% of all cancers in women. The global incidence of breast cancer is increasing, making it a significant public health problem. Advances in breast cancer management, including surgery, chemotherapy, radiotherapy, and hormone therapy, have contributed to reduced mortality rates. However, despite these positive developments, chemotherapy-related cognitive impairment, commonly referred to as "chemobrain," may occur.
Chemotherapy-induced cognitive impairment may manifest as deficits in memory, learning, attention, motor functions, executive functions, visual-spatial abilities, and information processing speed. These impairments negatively affect patients' quality of life and daily functioning.
In this study, cognitive education activities were designed and implemented to address these impairments. These activities aimed to support attention, memory, and executive functions and to minimize cognitive deficits. The purpose of this study was to examine the effects of cognitive activities applied to breast cancer patients receiving chemotherapy on cognitive functions, depression levels, and odor recognition abilities.
The study sought to answer the following research questions:
- What is the effect of cognitive education activities on odor recognition ability in breast cancer patients receiving chemotherapy?
- What is the effect of cognitive education activities on cognitive functions in breast cancer patients receiving chemotherapy?
- What is the effect of cognitive education activities on depression levels in these patients?
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Etlik
-
Ankara, Etlik, Turchia (Türkiye), 06010
- Health Sciences University Gulhane Training and Research Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
Participants were eligible if they met all of the following criteria:
- Aged between 18 and 65 years
- Literate
- Diagnosed with breast cancer
- Had received at least one cycle of chemotherapy and were currently undergoing chemotherapy
- Had a Standardized Mini-Mental Test (SMMT) score of 24 or below
- Had no diagnosed cognitive, neurological, or psychiatric disorder prior to chemotherapy
Exclusion Criteria:
Participants were excluded if they met any of the following criteria:
- Age over 65 years
- SMMT score above 24
- Presence of brain metastases
- Presence of neurological or medical conditions affecting cognitive function
- Diagnosed psychiatric disorder
- Current use of central nervous system depressants, stimulants, or psychiatric medications
- History of alcohol or substance abuse
Withdrawal Criteria:
Participants were withdrawn from the study if any of the following occurred:
- Discontinuation of chemotherapy treatment
- Inability to attend follow-up visits regularly
- Failure to complete the cognitive activity booklet tasks
- Loss of contact or inability to reach the participant
- Voluntary withdrawal from the study
- Death during the study period
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Control Group (Routine Care)
Participants in the control group received routine chemotherapy follow-up and standard care without any additional cognitive intervention during the study period.
|
|
|
Sperimentale: Intervention Group (Cognitive Education)
Participants in the intervention group received structured cognitive function training activities in addition to routine care.
The intervention was delivered using printed activity booklets designed to support cognitive function.
|
Participants received structured cognitive training through printed activity booklets designed to support attention, memory, executive functions, and language skills.
The booklets included activities such as puzzles, word derivation, sentence completion, pattern recognition, coloring, reading comprehension, and sudoku.
Four booklets with progressively increasing difficulty levels were provided over a 12-week period.
Each booklet was designed to be completed over three weeks.
The intervention was supported by face-to-face sessions and weekly telephone follow-ups to enhance adherence.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Cognitive Function (Standardized Mini-Mental Test)
Lasso di tempo: From baseline to the end of the 12-week intervention period
|
Cognitive function was assessed using the Standardized Mini-Mental State Examination (SMMSE/SMMT).
The scale evaluates global cognitive status across domains including orientation, registration, attention and calculation, recall, and language.
Scores range from 0 to 30, where 30 represents maximum cognitive function and scores below 24 may indicate cognitive impairment.
Higher scores indicate better cognitive performance.
|
From baseline to the end of the 12-week intervention period
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Subjective Cognitive Function (Functional Assessment of Cancer Therapy - Cognitive Function)
Lasso di tempo: From baseline to the end of the 12-week intervention period
|
Subjective cognitive function was assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3.
This self-report scale consists of 37 items categorised into four subscales: Perceived Cognitive Impairment, Comments from Others, Perceived Cognitive Abilities, and Impact of Cognitive Impairment on Quality of Life.
Each item is rated on a 5-point Likert scale (0=Not at all to 4=Very much), with higher total scores indicating better perceived cognitive health and fewer cognitive complaints.
|
From baseline to the end of the 12-week intervention period
|
|
Change in Depression Level (Beck Depression Inventory)
Lasso di tempo: From baseline to the end of the 12-week intervention period
|
Depression levels were assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale evaluating the severity of depressive symptoms.
Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms.
|
From baseline to the end of the 12-week intervention period
|
|
Odor Recognition Ability
Lasso di tempo: From baseline to the end of the 12-week intervention period
|
Odor recognition ability was assessed using a structured odor identification test consisting of 8 common odors presented in opaque (non-transparent) containers.
Participants were asked to smell each container and indicate whether they could correctly recognize the odor.
The assessment was based on whether each odor was correctly identified or not, rather than a numerical scoring system.
The odors included familiar scents such as coffee, lavender, lemon, orange, onion, rose water, cinnamon, and mint.
|
From baseline to the end of the 12-week intervention period
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Gizem Erdoğan, Hemşire, Health Sciences University Gulhane Training and Research Hospital
- Direttore dello studio: Betülay Kılıç, Doçent Doktor, Health Sciences University Gulhane Faculty of Nursing
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Neoplasie per sede
- Neoplasie
- Sintomi comportamentali
- Disturbi neurocognitivi
- Disturbi cognitivi
- Disturbi indotti chimicamente
- Malattie della pelle
- Malattie del seno
- Effetti collaterali correlati al farmaco e reazioni avverse
- Disfunzione cognitiva
- Comportamento
- Malattie della pelle e del tessuto connettivo
- Compromissione cognitiva correlata alla chemioterapia
- Depressione
- Neoplasie mammarie
Altri numeri di identificazione dello studio
- Decision No. 2025/23
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti